Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology.

Protease specificity determination by using cellular libraries of peptide substrates (CLiPS). Proc Natl Acad Sci U S A (2006) 1.33

The extended cleavage specificity of human thrombin. PLoS One (2012) 0.99

Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie (2010) 0.97

Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.89

High throughput substrate phage display for protease profiling. Methods Mol Biol (2009) 0.86

Kallikreins - The melting pot of activity and function. Biochimie (2015) 0.82

Substrate specificity of human kallikreins 1 and 6 determined by phage display. Protein Sci (2008) 0.80

Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics. J Biol Chem (2015) 0.79

Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity. J Biol Chem (2014) 0.77

A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity. J Biol Chem (2015) 0.76

A new method to assay protease based on amyloid misfolding: application to prostate cancer diagnosis using a panel of proteases biomarkers. Theranostics (2014) 0.76

Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol (2003) 2.50

In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res (2007) 1.35

Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol Int (2005) 1.03

Evaluation of the CFP-substrate-YFP system for protease studies: advantages and limitations. Biotechniques (2004) 1.00

Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J Clin Invest (2008) 1.00

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia (2012) 0.98

MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res (2005) 0.97

Major role of human KLK14 in seminal clot liquefaction. J Biol Chem (2008) 0.88

Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol Chem (2005) 0.82

In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts. Cancer Immun (2003) 0.82

Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clin Cancer Res (2008) 0.81

Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates. Clin Cancer Res (2006) 0.81

Activation and enzymatic characterization of recombinant human kallikrein 8. Biol Chem (2006) 0.81

Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates. Eur J Biochem (2004) 0.80

Late effects of sleep restriction: Potentiating weight gain and insulin resistance arising from a high-fat diet in mice. Obesity (Silver Spring) (2014) 0.80

Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells. Int J Cancer (2006) 0.79

Biophysical characterization of the interaction of endotoxins with hemoglobins. Med Chem (2007) 0.79

CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunol Immunother (2012) 0.78

Profiling of proteolytic activities secreted by cancer cells using phage display substrate technology. Tumour Biol (2004) 0.78

Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. Protein Eng Des Sel (2008) 0.77

A fetal sheep liver extract containing immunostimulatory substances including LPS acts as leukocyte activator in cells of LPS responder and non responder mice. Int Immunopharmacol (2005) 0.77

Expression and activity of thimet oligopeptidase (TOP) are modified in the hippocampus of subjects with temporal lobe epilepsy (TLE). Epilepsia (2014) 0.77

Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. Int J Cancer (2004) 0.77

Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. FEBS J (2006) 0.76

Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. Mol Cancer (2011) 0.76

In memory of Garry Abelev 1928-2013. Tumour Biol (2014) 0.75

An infrared reflection-absorption spectroscopic (IRRAS) study of the interaction of lipid A and lipopolysaccharide Re with endotoxin-binding proteins. Med Chem (2009) 0.75